timothy sykes logo
RVMD Stock Rallies As RASONQUE Launch And EU Nod Fuel Hype Thumbnail
G Google News

RVMD Stock Rallies As RASONQUE Launch And EU Nod Fuel Hype

TIM SYKES•UPDATED OCT. 20, 2026, 4:47 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Revolution Medicines Inc – Ordinary Shares stocks have been trading up by 7.89 percent after promising oncology pipeline progress news

Key Takeaways

  • FDA approved RASONQUE for previously treated metastatic pancreatic cancer, with Phase 3 data showing roughly doubled survival versus chemotherapy and about a 60% drop in risk of death.
  • A positive EMA CHMP opinion backs EU marketing approval for RASONQUE as a second-line pancreatic cancer therapy, setting up the first broad RAS‑targeted option in Europe if finalized.
  • Major Wall Street desks rate Revolution Medicines (RVMD) Buy/Outperform, with price targets around $241–$264 and a consensus near $259, versus a recent price under $200.
  • RBC flags strong early demand for RASONQUE, pegging about $36M in estimated Q3 launch revenue and solid patient conversions from an access program.
  • TD Cowen defends RVMD after a sharp selloff on G12D concerns, calling the reaction overdone and highlighting a best‑in‑class G12D inhibitor still in development.

Candlestick Chart

Live Update At 16:46:40 EDT: On Tuesday, October 20, 2026 Revolution Medicines Inc – Ordinary Shares stock [NASDAQ: RVMD] is trending up by 7.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RVMD has flipped from a pre‑revenue story to a commercial oncology name, and the chart shows traders are paying attention. Over the recent stretch, Revolution Medicines has chopped between roughly $176 and $211, with a latest close near $196.55. That puts RVMD below prior highs but well above the recent dip, a classic “buy-the-panic, sell-the-spike” playground for active trading.

Intraday action shows tight ranges between $195 and $197 for most of the afternoon, signaling consolidation after the news surge. For momentum traders, that kind of sideways chop after a run often sets up a secondary move — either a breakout if fresh catalysts hit, or a fade if enthusiasm dries up.

More Breaking News

Fundamentally, Revolution Medicines is still deep in the red. The latest quarter shows about -$644M in net loss and operating cash burn over -$741M. Return on equity and assets are sharply negative, while price‑to‑book near 15.6 screams “story stock,” not value play. The positive? RVMD sits on heavy cash — roughly $3.9B including short‑term investments — with a strong current ratio above 11 and limited debt. That runway gives RVMD time to let RASONQUE and the broader RAS pipeline prove themselves, which matters when you trade biotech hype cycles.

Why Traders Are Watching RVMD Now

RVMD is on traders’ screens because the story just shifted in a big way. Revolution Medicines now has FDA approval for RASONQUE (daraxonrasib) in previously treated metastatic pancreatic cancer, and the Phase 3 data are not incremental — they are step‑change. Doubling overall and progression‑free survival versus chemo and cutting risk of death by about 60% is the kind of efficacy that can rewire a treatment landscape.

On top of that, the EMA’s CHMP has issued a positive opinion recommending EU marketing authorization for RASONQUE as a second‑line treatment. If the European Commission signs off, RVMD will hold the first broad RAS‑targeted option for metastatic pancreatic cancer in Europe. For traders, that screams “global ramp” and opens a second major market just as the U.S. launch starts gaining traction.

The Street is leaning into the RVMD story. RBC Capital, BofA, Truist, and William Blair all rate Revolution Medicines at Buy or Outperform, with targets generally clustered from $241 to $264 and consensus near $259 while the stock recently traded under $200. RBC points to roughly $36M in estimated Q3 RASONQUE launch revenue and strong early patient conversions from an access program. Truist just bumped its RASONQUE Q3 revenue estimate from $14.3M to $19.5M, yet still calls its assumptions conservative.

William Blair talks about RVMD potentially owning the second‑line pancreatic cancer standard of care and pushing into earlier lines. That’s a much bigger, longer‑tail revenue picture than a tiny niche label. At the same time, TD Cowen stepped in after a sharp RVMD selloff on G12D mutation worries, arguing the hit was overdone and noting consistent survival metrics across subtypes plus a best‑in‑class G12D inhibitor still in the pipeline. Net result: the data and the analyst chatter both point in the same direction — this is a high‑beta growth name with catalysts, not a busted biotech.

Conclusion

For active traders, RVMD is a classic high‑reward biotech mover: clear catalyst, big gap between current numbers and future potential, and plenty of volatility. Revolution Medicines now has validated clinical data, FDA approval, and a positive EU opinion backing RASONQUE as a survival‑changing drug in metastatic pancreatic cancer. Analysts piling on Buy and Outperform ratings, with price targets well above the recent sub‑$200 quote, add fuel to the momentum narrative around RVMD.

At the same time, the financials remind you why this stays a trading vehicle, not a sleepy hold. Revolution Medicines is burning hundreds of millions per quarter, with negative earnings and returns, and the share price still reflects a rich multiple on future promise. If RASONQUE launch numbers or upcoming colorectal cancer updates in 2026 stumble, RVMD can unwind fast. The five‑minute chart’s tight intraday range shows consolidation now, but biotech history says that calm rarely lasts.

This is where discipline separates pros from bag‑holders. As Tim Sykes likes to hammer home, “Cut losses quickly; small losses are fine, big losses are unacceptable.” As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” For anyone trading RVMD, that mindset is critical. Respect the volatility, trade the catalysts, and remember this article is for educational and research purposes only — not a signal to buy or sell RVMD or any other stock.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”